Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
Business Wire•05/11/2026•16:01 ET
0
Key Highlights
- ➤ARCT-032 Phase 2 enrollment expected to complete by year-end 2026
- ➤ARCT-2601 Phase 2 dosing planned for Q1 2027, top-line data H2 2027
- ➤LUNAR 2.0 demonstrated 38-fold greater potency than ARCT-810’s key lipid
- ➤Third-quarter revenue $18.3 million, up from $17.2 million year over year
- ➤Third-quarter net loss narrowed to $7.4 million from $13.4 million
Expert Statements
Joseph Payne, President & CEO of Arcturus Therapeutics
“The third quarter marked a pivotal step forward for our liver therapeutics franchise, with encouraging ARCT-810 Phase 2 results and the introduction of LUNAR 2.0™, our next-generation mRNA delivery platform, which demonstrated a 38-fold improvement over the key lipid in ARCT-810 in non-human primates”
Joseph Payne, President & CEO of Arcturus Therapeutics
“We look forward to presenting data from our CF program in Q2 2027, followed by initial potential proof-of-concept data from ARCT-2601, our LUNAR 2.0™-formulated mRNA therapeutic for OTC deficiency, in H2 2027.”
Dennis Mulroy, Chief Financial Officer of Arcturus Therapeutics
“We prioritize disciplined investment in the programs and technologies that we believe will create the greatest long-term value,”
Dennis Mulroy, Chief Financial Officer of Arcturus Therapeutics
“We continue to maintain a strong balance sheet and cash runway of over two years through year end 2028, allowing our company to reach important clinical and regulatory milestones for its rare disease pipeline.”
Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
ARCT-032 (CF) Phase 2 enrollment completion YE 2026; data presentation Q2 2027
Get started
Create a free account to read the full story.